Literature DB >> 9249256

Characterization of putative 5-HT7 receptors mediating tachycardia in the cat.

C M Villalón1, J P Heiligers, D Centurión, P De Vries, P R Saxena.   

Abstract

1. It has been suggested that the tachycardic response to 5-hydroxytryptamine (5-HT) in the spinal-transected cat is mediated by '5-HT1-like' receptors since this effect, being mimicked by 5-carboxamidotryptamine (5-CT), is not modified by ketanserin or MDL 72222, but it is blocked by methiothepin, methysergide or mesulergine. The present study was set out to reanalyse this suggestion in terms of the IUPHAR 5-HT receptor classification schemes proposed in 1994 and 1996. 2. Intravenous (i.v.) bolus injections of the tryptamine derivatives, 5-CT (0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 30 microg kg(-1)), 5-HT (3, 10 and 30 microg kg(-1)) and 5-methoxytryptamine (3, 10 and 30 microg kg(-1)) as well as the atypical antipsychotic drug, clozapine (1000 and 3000 microg kg(-1)) resulted in dose-dependent increases in heart rate, with a rank order of agonist potency of 5-CT >> 5-HT > 5-methoxytryptamine >> clozapine. 3. The tachycardic effects of 5-HT and 5-methoxytryptamine were dose-dependently antagonized by i.v. administration of lisuride (30 and 100 microg kg(-1)), ergotamine (100 and 300 microg kg(-1)) or mesulergine (100, 300 and 1000 microg kg(-1)); the highest doses of these antagonists used also blocked the tachycardic effects of 5-CT. Clozapine (1000 and 3000 microg kg(-1)) did not affect the 5-HT-induced tachycardia, but attenuated, with its highest dose, the responses to 5-methoxytryptamine and 5-CT. However, these doses of clozapine as well as the high doses of ergotamine (300 microg kg(-1)) and mesulergine (300 and 1000 microg kg(-1)) also attenuated the tachycardic effects of isoprenaline. In contrast, 5-HT-, 5-methoxytryptamine- and 5-CT-induced tachycardia were not significantly modified after i.v. administration of physiological saline (0.1 and 0.3 ml kg(-1)), the 5-HT(1B/1D) receptor antagonist, GR127935 (500 microg kg(-1)) or the 5-HT(3/4) receptor antagonist, tropisetron (3000 microg kg(-1)). 4. Intravenous injections of the 5-HT1 receptor agonists, sumatriptan (30, 100 and 300 microg kg(-1)) and indorenate (300 and 1000 microg kg(-1)) or the 5-HT4 receptor (partial) agonist cisapride (300 and 1000 microg kg(-1)) were devoid of effects on feline heart rate per se and failed to modify significantly 5-HT-induced tachycardic responses. 5. Based upon the above rank order of agonist potency, the failure of sumatriptan, indorenate or cisapride to produce cardioacceleration and the blockade by a series of drugs showing high affinity for the cloned 5-ht7 receptor, the present results indicate that the 5-HT receptor mediating tachycardia in the cat is operationally similar to other putative 5-HT7 receptors mediating vascular and non-vascular responses (e.g. relaxation of the rabbit femoral vein, canine external carotid and coronary arteries, rat systemic vasculature and guinea-pig ileum). Since these responses represent functional correlates of the 5-ht7 gene product, the 5-HT7 receptor appellation is reinforced. Therefore, the present experimental model, which is not complicated by the presence of other 5-HT receptors, can be utilized to characterize and develop new drugs with potential agonist and antagonist properties at functional 5-HT7 receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249256      PMCID: PMC1564807          DOI: 10.1038/sj.bjp.0701260

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  Atrial fibrillation associated with sumatriptan.

Authors:  D R Morgan; M Trimble; G E McVeigh
Journal:  BMJ       Date:  2000-07-29

2.  Molecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT(1B) receptor.

Authors:  P Bhalla; H S Sharma; X Ma; T Wurch; P J Pauwels; P R Saxena
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 3.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

4.  Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle.

Authors:  N H Prins; M R Briejer; P J Van Bergen; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

5.  The atypical 5-HT2 receptor mediating tachycardia in pithed rats: pharmacological correlation with the 5-HT2A receptor subtype.

Authors:  David Centurión; Mario I Ortiz; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors.

Authors:  C M Villalón; P De Vries; G Rabelo; D Centurión; A Sánchez-López; P Saxena
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

7.  Identification of the adenylyl cyclase-activating 5-hydroxytryptamine receptor subtypes expressed in the rat submandibular gland.

Authors:  D M Bourdon; J M Camden; L A Landon; F O Levy; J T Turner
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

8.  Sustained Hypoxia Elicits Competing Spinal Mechanisms of Phrenic Motor Facilitation.

Authors:  Michael J Devinney; Nicole L Nichols; Gordon S Mitchell
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

9.  Dilatation induced by 5-HT in the middle meningeal artery of the anaesthetised cat.

Authors:  Geoffrey Andrew Lambert; Cathy Donaldson; Karen Lisa Hoskin; Peter Michael Boers; Alessandro Stefano Zagami
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-05-07       Impact factor: 3.000

Review 10.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.